Anti-CD38 Quadruplet Induction Regimens in TE NDMM: New Standard of Care

Opinion
Video

Panelists discuss how while daratumumab-based quadruplet regimens are increasingly becoming the standard of care for patients with transplant-eligible newly diagnosed multiple myeloma (TE NDMM) due to superior efficacy data, certain factors like frailty, comorbidities, and cost considerations may still warrant triplet therapy in select cases.

Video content above is prompted by the following:

  • From your experience, do you believe that daratumumab-based quadruplet induction regimens are the new standard of care for TE NDMM patients?
  • In which patients would you consider induction with a triplet regimen?
Recent Videos
3 experts in this video
Related Content
Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.

Isatuximab Combo Earns Chinese Approval in R/R Multiple Myeloma

Russ Conroy
January 16th 2025
Article

Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.

Data Show Enduring Efficacy with Anito-cel in R/R Multiple Myeloma

Kristi Rosa
December 30th 2024
Article

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Experts Discuss Choosing Bispecifics and Sequencing Options in Multiple Myeloma

Experts Discuss Choosing Bispecifics and Sequencing Options in Multiple Myeloma

ONCOLOGY Staff
December 27th 2024
Article

During the 2024 IMS conference, teams from Cleveland, Ohio, and New York, New York, met to debate the latest advances in multiple myeloma.

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.

Arlo-cel Shows Promising Efficacy in Pretreated R/R Multiple Myeloma

Gina Mauro
December 27th 2024
Article

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.